US2020299760A1PendingUtilityA1

Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna

73
Assignee: UNIV LELAND STANFORD JUNIORPriority: Apr 7, 2016Filed: Apr 15, 2020Published: Sep 24, 2020
Est. expiryApr 7, 2036(~9.7 yrs left)· nominal 20-yr term from priority
Inventors:Chunxiao SongStephen R. Quake
C12Q 1/6869C12N 15/00C12Q 1/6806C12Q 1/6855C12Q 1/6886C12Q 2525/191C12Q 2600/154C40B 50/04C12Q 2563/185C40B 70/00C12Q 2545/101C40B 40/08
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein is a method of sequencing hydroxymethyated cell-free DNA. In some embodiments, the method comprises adding an affinity tag to only hydroxymethyated DNA molecules in a sample of cfDNA, enriching for the DNA molecules that are tagged with the affinity tag; and sequencing the enriched DNA molecules.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A kit for analyzing cfDNA, comprising:
 DNA β-glucosyltransferase;   UDP glucose modified with a chemoselective group;   an adaptor comprising at least one molecular barcode; and   a spiked-in control comprising three amplicons synthesized from a cocktail of dATP, dGTP, dTTP, and (1) dCTP, (2) dmCTP, or (3) dhmCTP and dCTP.   
     
     
         2 . The kit of  claim 1 , wherein the at least one molecular barcode comprises a sample identifier sequence and a molecule identifier sequence.

Join the waitlist — get patent alerts

Track US2020299760A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.